Comparison of recent trials in high-risk pediatric HL
| Study group/trial . | Sample size . | Chemotherapy . | Radiotherapy . | EFS or DFS, % . | OS, % . | Follow-up, y . |
|---|---|---|---|---|---|---|
| Children's Cancer Group CCG-59704 | 98 | 4 BEACOPP + M RER: 2 ABVD F RER: 4 COPP/ABV SER: 4 BEACOPP | 21 Gy IFRT (no RT for F RER) | 94 | 97 | 6 |
| Pediatric Oncology Group P942515 | 163 | 3 DBVE-PC ± 2 DBVE-PC | 21 Gy IFRT | 85 | NR | 5 |
| Children's Cancer Group CCG-59421 | 141 | COPP/ABV + CHOP + cytarabine/etoposide | ± 21 Gy IFRT | 82 | 93 | 3 |
| Stanford/St Jude/Dana-Farber25 | 159 | 3 VAMP/ 3 COP | 15-25.5 Gy IFRT | 75.6 | 92.7 | 5 |
| German Multicenter GPOH HD-9526 | 341 | 2 OPPA/OEPA + 4 COPP | 20-35 Gy IFRT (no RT if CR) | 83 (CR 79; PR 91) | NR | 3 |
| German Multicenter GPOH HD-200227 | 239 | 2 OPPA/OEPA + 4 COPADC | 19.8-35 Gy IFRT | 87 | 95 | 5 |
| Study group/trial . | Sample size . | Chemotherapy . | Radiotherapy . | EFS or DFS, % . | OS, % . | Follow-up, y . |
|---|---|---|---|---|---|---|
| Children's Cancer Group CCG-59704 | 98 | 4 BEACOPP + M RER: 2 ABVD F RER: 4 COPP/ABV SER: 4 BEACOPP | 21 Gy IFRT (no RT for F RER) | 94 | 97 | 6 |
| Pediatric Oncology Group P942515 | 163 | 3 DBVE-PC ± 2 DBVE-PC | 21 Gy IFRT | 85 | NR | 5 |
| Children's Cancer Group CCG-59421 | 141 | COPP/ABV + CHOP + cytarabine/etoposide | ± 21 Gy IFRT | 82 | 93 | 3 |
| Stanford/St Jude/Dana-Farber25 | 159 | 3 VAMP/ 3 COP | 15-25.5 Gy IFRT | 75.6 | 92.7 | 5 |
| German Multicenter GPOH HD-9526 | 341 | 2 OPPA/OEPA + 4 COPP | 20-35 Gy IFRT (no RT if CR) | 83 (CR 79; PR 91) | NR | 3 |
| German Multicenter GPOH HD-200227 | 239 | 2 OPPA/OEPA + 4 COPADC | 19.8-35 Gy IFRT | 87 | 95 | 5 |
DFS indicates disease-free survival; M, male; F, female; COPP, cyclophosphamide, vincristine, procarbazine, prednisone; DBVE-PC, doxorubicin; bleomycin, vincristine, etoposide, prednisone, cyclophosphamide; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; VAMP, vinblastine, doxorubicin, methotrexate, prednisone; OPPA, vincristine, procarbazine, prednisone, doxorubicin; OEPA, vincristine, etoposide, prednisone, doxorubicin; COPDAC, cyclophosphamide, vincristine, prednisone, dacarbazine; IFRT, involved field radiation therapy; and NR, not reported.